Greg Byrne, an 87-year-old melanoma trial participant from Arizona, bought shares of Moderna when he enrolled in an experimental mRNA cancer vaccine study two years ago, according to the Wall Street Journal. Moderna stock soared more than 150% last week following successful experimental results, turning the long-held position into a notable personal gain tied to the same research program in which he took part.